Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2013

View Archived Issues

Dopamine D2 receptor PAMs for Parkinson's disease

Cancer Genetics launches FHACT test

US WorldMeds begins trial of Myobloc to treat sialorrhea

Collaboration to focus on 17-beta-HSD 1 inhibitor for endometriosis and estrogen-dependent cancers

RaQualia and Asahi Kasei Pharma sign joint research agreement

Phase III study of MLN-9702 for relapsed/refractory multiple myeloma opens to Japanese patients

Shionogi licenses pain products for Japan from Mundipharma

Recombinant tetravalent glycoprotein vaccine V-180 for dengue virus

Major role for rare heterozygous truncating mutations in autism etiology identified

Japanese researchers present novel peripheral blood lymphocyte-reducing agents

Carna Biosciences presents new BTK inhibitors

U.S. and Canadian team synthesizes novel PAR-4 antagonists for thromboembolism

Toleranzia discloses novel immunotolerizing fusion proteins for multiple sclerosis

Retrophin patents novel vitamin B5 prodrugs

Neuronascent Alzheimer's disease candidate advances to IND-enabling studies

AbbVie reports on first of six phase III studies of interferon-free, 12-week HCV regimen

Defibrotide receives European orphan drug designation for GVHD

Viriom expands licensing agreement with Roche for VM-1500

Clinical results for K-877, a novel PPAR-alpha receptor agonist, presented

Horizon Pharma to acquire U.S. rights to Vimovo

Consortium launches EPITARGET project focused on epileptogenesis and epilepsy

Project A.L.S. and Lilly team up on ALS research

Once-daily inhaled COPD agent launched in Japan

Topokine Therapeutics initiates phase II study of XAF-5 gel

Phase III SYNERGY trial of custirsen recommended to continue

European approval for Kadcyla

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.